Jennifer L. Moseley

Suggest Changes
  • Citations Per Year
Learn More
Background:Dinaciclib is a potent inhibitor of cell cycle and transcriptional cyclin-dependent kinases. This Phase 1 study evaluated the safety, tolerability and pharmacokinetics of various dosing(More)
  • 1